Are we about to develop a Covid-19 vaccine that is resistant to the variant?

Efforts to develop a “holy grail” vaccine that could be effective against all future Covid variants are underway but it could take years until a vaccine like ready for widespread use.

While a new Covid vaccine can now be developed within weeks to protect against an emerging variant, scientists hope to develop a single vaccine that can work against any conceivable mutation of Covid-19.

The first wave of vaccines was designed to neutralize the original strain of the virus, which was originally identified in Wuhan. Scientists are currently working to develop a fighter drug that can provide long-lasting immunity, no matter what new variant comes out.

However, how quickly they can achieve this is another question. For generations, scientists have struggled in vain to create a vaccine that broadly protects against flu mutations.

Enhanced vaccine trial “anti-variant” started in Manchester last year. Andrew and Helen Clarke from Bolton, 63 and 64 years old respectively at the time, were the first test participants to receive the new aircraft

The Coalition for Epidemic Preparedness Innovations (CEPI) has launched a $200 million research program to discover vaccines that provide broad protection against future variants, Vaccines today in December.

A promising partnership in development with UK-based biotech company DIOSynVax, led by Cambridge University professor Jonathan Heeney, will receive grants of up to 32 million pound from CEPI, Time reported.

The article says this is one of a number of potential fighters that seek to “target parts of the virus that are less likely to mutate”. If Heeney’s team can identify the “immutable” parts of the virus, it makes sense that a vaccine “could protect not only against variants but also against new coronaviruses.” and growing in the future”.

The vaccine uses “different technology” from other leading injections. Previous vaccines have introduced the mutant coronavirus protein into the body in the hope that we learn to “recognize” the virus’s mutant protein and fight it. But this method “encourages” the virus to evolve to evade protection by altering its spike rate.

“All the vaccines we are still using today are based on the Wuhan sequence from January 2020. “It is not surprising that we have to step up and promote and push, because we’re losing the effect as the virus moves out of that sequence.”

By using a “different design of the protein,” DIOSynVax hopes their vaccine could be used to “provide protection against the variant, but also potentially be ready for use in the there’s another coronavirus pandemic,” said The Times. It can also be delivered through the use of “refined” Pfizer or Oxford vaccine platforms.

CBS News reported last month that T cells generated as part of the body’s natural immune response to the common cold could provide a breakthrough. A study at Imperial College London could help scientists create a more effective maintenance vaccine against new variants of the coronavirus, say researchers at Imperial College London.

They found that 26 people who were exposed to Covid-19 but did not get sick had significantly higher cross-reactive T cells, produced by the previous common cold, than those who had become ill with Covid.

“The fact that (T cells) can attack the internal proteins of each of these related viruses [COVID-19 variants] which means they give so-called broad cross-protection,” says Professor Aljit Lalvani. “That is in sharp contrast to the surface spike protein, which is the target of antibodies caused by [current] Vaccine.”

He said the results of the study were “a definitive green light” for developing a “T-cell-inducible vaccine with core proteins inside, which could protect against current and future variants.” “.

Meanwhile, across the Atlantic, the US military is also testing a vaccine designed to protect against all variants, reports Quartz.

The Spike Ferritin Nanoparticle (SpFN) vaccine was successfully tested in animals last year, and phase one trials have shown positive results, one of the research groups said. Next, it will undergo phase two and phase three trials, where researchers can determine its effectiveness.

Elsewhere in the US, Barton Haynes, director of the Human Vaccine Institute at Duke University School of Medicine, and his team are working on a vaccine that triggers neutralizing antibodies and immune responses different for all Sars-Cov-2 variants to date. Haynes hopes it will also work against variations that emerge in the near future.

However, an anti-collision variant is not expected anytime soon. Cepi’s aim is to have a proof of concept for such a collision “within the 2023 timeframe”. Melanie Saville, director of vaccine research and development, told the FT that it would then take another year or two to be approved for use.

So for a vaccine that really protects, “we’re really looking at the 2024 to 2025 timeframe… so that’s a long way off,” she added. Anthony Fauci, the chief medical adviser to US President Joe Biden, agrees that it will take some time. “You’re not going to hit the home run the first time you take the throne, that’s for sure,” he said. Are we about to develop a Covid-19 vaccine that is resistant to the variant?

Fry Electronics Team

Fry is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button